Sonoma Biotherapeutics develops engineered regulatory T-cell (TREG) therapies aimed at treating autoimmune and inflammatory diseases by restoring immune system balance. The company employs proprietary cell-therapy platform technologies to engineer and deliver targeted TREG approaches designed for durable, disease-modifying treatment. Its services include preclinical development, clinical evaluation of TREG-based therapies, and collaboration frameworks for advancing new modalities in immune-mediated conditions. Sonoma Biotherapeutics engages with partners and stakeholders across research, manufacturing, and clinical operations to bring engineered cell therapies from concept toward clinical proof of concept.